Feasibility and efficacy of neoadjuvant sunitinib before nephron‐sparing surgery

Abstract

Neoadjuvant TKI followed by NSS is safe and feasible, with all patients achieving a reduction in maximum tumour diameter, and with NSS being achievable with negative margins and with no requirement for postoperative dialysis. Further investigation is required.